Radiopharm Theranostics Limited American Depositary Shares

Radiopharm Theranostics Limited is a clinical-stage radiotherapeutics company focused on the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. Its pipeline includes RAD101 and RAD102 for brain metastasis, RAD201a and RAD202 for HER-2 breast cancer, RAD203 and RAD204 for PDL1 non-small cell lung cancer, RAD301 and RAD302 for Avß6-Integrin pancreatic cancer, RAD401 and RAD402 for PSA-mAb prostate cancer, and RAD601 and RAD602 for PTPµ glioblastoma. The company has a strategic agreement with Lantheus Holdings, Inc. to advance clinical development of radiopharmaceuticals. Incorporated in 2021, it is based in Carlton, Australia.